Publicación:
Vacunas SARS-CoV-2: evolución y escape

Vista sencilla de ítem
dc.contributor.authorRivero-Herrera, Ricardospa
dc.contributor.authorGonzález-Tous, Marcospa
dc.contributor.authorMattar, Salimspa
dc.date.accessioned2021-05-02 00:00:00
dc.date.accessioned2022-07-01T21:01:51Z
dc.date.available2021-05-02 00:00:00
dc.date.available2022-07-01T21:01:51Z
dc.date.issued2021-05-02
dc.format.mimetypeapplication/pdfspa
dc.format.mimetypeapplication/pdfspa
dc.format.mimetypeapplication/zipspa
dc.format.mimetypeapplication/zipspa
dc.format.mimetypeapplication/xmlspa
dc.format.mimetypeapplication/xmlspa
dc.format.mimetypeaudio/mpegspa
dc.format.mimetypeaudio/mpegspa
dc.identifier.doi10.21897/rmvz.2372
dc.identifier.eissn1909-0544
dc.identifier.issn0122-0268
dc.identifier.urihttps://repositorio.unicordoba.edu.co/handle/ucordoba/6132
dc.identifier.urlhttps://doi.org/10.21897/rmvz.2372
dc.language.isospaspa
dc.publisherUniversidad de Córdobaspa
dc.relation.bitstreamhttps://revistamvz.unicordoba.edu.co/article/download/e2372/2982
dc.relation.bitstreamhttps://revistamvz.unicordoba.edu.co/article/download/e2372/2983
dc.relation.bitstreamhttps://revistamvz.unicordoba.edu.co/article/download/e2372/3484
dc.relation.bitstreamhttps://revistamvz.unicordoba.edu.co/article/download/e2372/3486
dc.relation.bitstreamhttps://revistamvz.unicordoba.edu.co/article/download/e2372/3485
dc.relation.bitstreamhttps://revistamvz.unicordoba.edu.co/article/download/e2372/3487
dc.relation.bitstreamhttps://revistamvz.unicordoba.edu.co/article/download/e2372/2984
dc.relation.bitstreamhttps://revistamvz.unicordoba.edu.co/article/download/e2372/2985
dc.relation.citationeditionNúm. 3 , Año 2021 : Revista MVZ Córdoba Volumen 26(3) Septiembre-Diciembre 2021spa
dc.relation.citationendpagee2372
dc.relation.citationissue3spa
dc.relation.citationstartpagee2372
dc.relation.citationvolume26spa
dc.relation.ispartofjournalRevista MVZ Córdobaspa
dc.relation.referencesWorldometer. COVID-19 coronavirus pandemic. [Internet]. Worldometer; 2021. Available from: https://www.worldometers.info/coronavirus/spa
dc.relation.referencesPremkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann AJ, et al. The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020; 5(48):eabc8413. https://doi.org/10.1126/sciimmunol.abc8413spa
dc.relation.referencesPolack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383(27):2603–2615. https://doi.org/10.1056/NEJMoa2034577spa
dc.relation.referencesBaden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384(5):403–416. https://doi.org/10.1056/NEJMoa2035389spa
dc.relation.referencesNIH. Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released. USA: National Institutes of Health (NIH); 2021. https://www.nih.gov/news-events/news-releases/janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-releasedspa
dc.relation.referencesAstraZeneca. COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials [Internet]. Cambridge, UK, AstraZeneca; 2021. https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.htmlspa
dc.relation.referencesLogunov DY, Dolzhikova I V., Shcheblyakov D V., Tukhvatulin AI, Zubkova O V., Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20; 397(10275):671–81. https://doi.org/10.1016/S0140-6736(21)00234-8spa
dc.relation.referencesSinovac Announces Phase III Results of Its COVID-19 Vaccine-SINOVAC - Supply Vaccines to Eliminate Human Diseases. Available from: http://www.sinovac.com/?optionid=754&auto_id=922spa
dc.relation.referencesWibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021; https://doi.org/10.1038/s41591-021-01285-xspa
dc.relation.referencesCallaway E. The coronavirus is mutating - does it matter? Nature. 2020; 585:174-177. https://doi.org/10.1038/d41586-020-02544-6spa
dc.relation.referencesWu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, et al. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. N Engl J Med. 2021. https://doi.org/10.1056/NEJMc2102179spa
dc.relation.referencesWang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021. https://doi.org/10.1038/s41586-021-03324-6spa
dc.relation.referencesGarcia-Beltran WF, Lam EC, St. Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021; 184:1-12. https://doi.org/10.1016/j.cell.2021.03.013spa
dc.relation.referencesvan Egeren D, Novokhodko A, Stoddard M, Tran U, Zetter B, Rogers M, et al. Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein. medRxiv. 2020; 11.17.20233726. https://doi.org/10.1101/2020.11.17.20233726spa
dc.relation.referencesWeisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife. 2020; 9: e61312. https://doi.org/10.7554/eLife.61312spa
dc.rightsRicardo Rivero-Herrera, Marco González-Tous, Salim Mattar - 2021spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/spa
dc.sourcehttps://revistamvz.unicordoba.edu.co/article/view/e2372spa
dc.subjectSARS-CoV-2eng
dc.subjectvaccineseng
dc.subjectviral strainseng
dc.subjectSARS-CoV-2spa
dc.subjectvacunasspa
dc.subjectcepas viralesspa
dc.titleVacunas SARS-CoV-2: evolución y escapespa
dc.title.translatedSARS-CoV-2 vaccines: evolution and escapeeng
dc.typeArtículo de revistaspa
dc.typeJournal articleeng
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.coarhttp://purl.org/coar/resource_type/c_b239spa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTEDITspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dspace.entity.typePublication
Archivos
Colecciones
HAJ. Revista MVZ